We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
4 peer-reviewed studies
What the evidence says
Most Strontium studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2002–2010.
Based on 4 studies · 2 meta-analyses
Confidence
HighBy outcome
Newest study from 2010 · Latest meta-analysis: 2010
A pooled analysis of large RCTs (SOTI/TROPOS) found strontium ranelate reduced vertebral fracture risk in postmenopausal osteoporosis, independent of baseline bone-turnover markers.
Collette J et al. · Osteoporos Int (2010)
A pooled analysis linked early bone-turnover-marker changes to bone-density (BMD) response — but markers were NOT significantly associated with fracture incidence.
Bruyere O et al. · Osteoporos Int (2010)
A review described strontium ranelate's dual action on bone formation and resorption in osteoporosis.
Reginster JY et al. · Curr Pharm Des (2002)
A review covered the physiological basis of strontium ranelate for optimizing bone strength.
Marie PJ et al. · Bone (2006)